A retrospective analysis of the efficacy of immune checkpoint inhibitors (ICIs) to advanced non-small cell cancer (NSCLC) patients (pts) with central nerve system (CNS) metastasis.

Published on Jun 1, 2018in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.2018.36.15_SUPPL.E21042
Takashi Sone12
Estimated H-index: 12
 (Kanazawa University), Kazuo Kasahara28
Estimated H-index: 28
 (Kanazawa University)+ 13 AuthorsHideharu Kimura21
Estimated H-index: 21
 (Kanazawa University)
Source
Abstract
e21042Background: In clinical practice of advanced NSCLC pts, a control of CNS metastasis is important issue. Several clinical trials of ICIs have demonstrated the survival benefit in advanced NSCL...
References0
Newest
Cited By1
Newest
Aug 1, 2018·Cancer Biology & Therapy3.66
#1Wang Jing (SDU: Shandong University)H-Index: 6
#2Haiyong Wang (SDU: Shandong University)H-Index: 9
Last. Hui Zhu (Academy of Medical Sciences, United Kingdom)H-Index: 7
view all 5 authors...
ABSTRACTLeptomeningeal metastases (LMs) were devastating metastatic complications of non-small cell lung cancer (NSCLC). Management of LMs relied on conventional therapy but with poor survival, lacking effective treatment strategies. We present the case of a 52-year-old female non-smoker with advanced lung adenocarcinoma and initially positive EGFR-mutation, who failed to the treatment of standard first-line chemotherapy (pemetrexed plus cisplatin) and bevacizumab (BEV), and maintenance therapy ...
2 CitationsSource
1